Diabetes

This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

Your daily dose of the clinical news you may have missed.

ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.

Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.

For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.

Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Your daily dose of the clinical news you may have missed.

Global prevalence of adults 65 years and older with T1D increased 180% in the past 30 years, researchers reported.

More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.

The panel of experts from UCSD concludes the discussion on delaying the onset of stage 3 T1D by providing key takeaways and clinical advice on the treatment of patients with this condition.

Focusing on the utilization of teplizumab, the expert panel from UCSD shares insights in how to select patients for this treatment and provide practical tips for the infusion process, and infusion location options.

The panel reviews the TN-10 trial investigating teplizumab, focusing on patient inclusion criteria, patient outcomes, and adverse reactions.

Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.

Schafer Boeder, MD and Andrea Stallings, PA delve into the intricacies of autoantibody screening tests for T1D with detailed insights on their methodologies, interpretation nuances, and practical analysis considerations.

Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.

Addressing the significance of acting early in T1D care, a group of diabetes experts delve into the impact of delaying intervention during stage 2 of the condition.

Schafer Boeder, MD and his colleagues provide a comprehensive overview of the stages of T1D in patients with diabetes, highlighting the various signs and symptoms associated with each stage.

A panel of experts on diabetes management introduce themselves and provide an overview of the condition, highlighting risk factors, disease burden, and the benefits of collaborative care.

Your daily dose of the clinical news you may have missed.

Abbott becomes the second company to receive FDA clearance for an over-the-counter continuous glucose monitoring system.

There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.

Your daily dose of the clinical news you may have missed.

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.